Skip to main content

Advertisement

Fig. 7 | Cell Communication and Signaling

Fig. 7

From: TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway

Fig. 7

TNFAIP8 regulates NSCLC proliferation and chemoresistance in vivo. Mice were treated with cisplatin (3.0 mg/kg body weight; i.p., three times per week) or with 0.1 ml of PBS (pH 7.4; i.p., three times per week). a Representative features of tumours at 28 days after inoculation using A549/Ctrl or A549/TNFAIP8-sh2 cells treated with PBS or cisplatin. b Tumours growth in the mice injected with A549/Ctrl or A549/TNFAIP8-sh2 cells treated with PBS or cisplatin. Inoculations were performed in 10 mice. c Tumour volumes at day 28 after the inoculation. Left (black column), average tumour volumes at day 28 after inoculation with A549/Ctrl or A549/TNFAIP8-sh2 cells in mice treated with PBS; right (white column), average tumour volumes at day 28 after inoculation of A549/Ctrl or A549/TNFAIP8-sh2 cells in mice treated with cisplatin. d qRT-PCR and Western blot analysis of the relative p53 expression in tumours originating from A549/Ctrl or A549/TNFAIP8-sh2 cells treated with PBS or cisplatin. Data are presented as the mean ± SEM (n = 3). e Proposed model for TNFAIP8-induced proliferation and cisplatin resistance in NSCLC. TNFAIP8-mediated p53 suppression activates the expression of cyclin D1 and RAD51, thus promoting cell cycle progression and DNA repair. These actions lead to NSCLC cell proliferation and cisplatin resistance

Back to article page